In this video, Philip J. Mease, MD, discusses a Nordic registry study presented at the EULAR annual meeting that showed the prevalence of “difficult-to-treat” psoriatic arthritis.

The study found that the percentage of patients categorized as having difficult-to-treat PsA varied significantly based on how the definition was applied.

“They found that up to 37% of patients who failed at least two [therapies], and up to 10% of the patients who had failed at least four fell into a difficult-to-treat definition,” said Mease, director of rheumatology research at Providence Swedish Medical Center, in Seattle.

The study is valuable because it provides real world evidence of the prevalence of difficult-to-treat patients in the PsA population, Mease said.

Reference:

Nielung LM. Abstract OP017

See Full Page